TRADING UPDATES: MedPal acquisition; Helix begins helium sales
20th Jul 2026 21:55
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
| Price | 33.50p on 25-08-2026 at 13:02:11 |
|---|---|
| Change | 4.50p 15.52% |
| Buy | 34.00p |
| Sell | 33.00p |
| Last Trade: | Buy 32,560.00 at 33.511p |
| Day's Volume: | 1,309,915 |
| Last Close: | 29.00p |
| Open: | 29.00p |
| ISIN: | GB00BMC3RJ87 |
| Day's Range | 29.00p - 34.00p |
| 52wk Range: | 9.00p - 34.00p |
| Market Capitalisation: | £46.93m |
| VWAP: | 31.89069p |
| Shares in Issue: | 140.09m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Sareum (SAR) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 32,560 | 33.511p | Ordinary |
14:02:10 - 25-Aug-26 |
| Unknown* | 1,500 | 33.50p | Ordinary |
13:58:32 - 25-Aug-26 |
| Buy* | 176 | 34.00p | Ordinary |
13:58:06 - 25-Aug-26 |
| Unknown* | 0 | 34.00p | SI Trade |
13:58:05 - 25-Aug-26 |
| Buy* | 53 | 34.00p | SI Trade |
13:58:05 - 25-Aug-26 |
| Buy* | 121 | 34.00p | SI Trade |
13:58:05 - 25-Aug-26 |
| Buy* | 5,000 | 33.70p | Ordinary |
13:57:58 - 25-Aug-26 |
| Buy* | 5,000 | 33.70p | Ordinary |
13:55:13 - 25-Aug-26 |
| Sell* | 8,475 | 33.15p | Ordinary |
13:54:34 - 25-Aug-26 |
| Sell* | 10,000 | 33.15p | Ordinary |
13:54:20 - 25-Aug-26 |
Sareum (SAR) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 19th Aug 2026 2:19 pm | RNS | Exercise of Warrants |
| 7th Aug 2026 1:28 pm | RNS | Exercise of Warrants |
| 20th Jul 2026 7:00 am | RNS | Completion of Dosing in Toxicology Programme |
| 22nd Jun 2026 9:40 am | RNS | Publication of Phase 1 data on SDC-1801 in BJCP |
| 1st May 2026 7:00 am | RNS | Exercise of Warrants |
| 12th Mar 2026 7:00 am | RNS | Half-Year Report for Six Months Ended 31 Dec 2025 |
| 12th Mar 2026 7:00 am | RNS | Half-Year Report for Six Months Ended 31 Dec 2025 |
| 3rd Mar 2026 7:00 am | RNS | Notice of Results and Investor Presentation |
| 17th Feb 2026 7:00 am | RNS | Restart of Phase 2-enabling toxicology programme |
| 23rd Jan 2026 4:36 pm | RNS | Form 8.3 - Oxford Biomedica plc |